Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Equities researchers at Seaport Res Ptn reduced their Q1 2025 earnings per share estimates for Curaleaf in a note issued to investors on Wednesday, March 5th. Seaport Res Ptn analyst S. Randhawa now expects that the company will earn ($0.07) per share for the quarter, down from their previous forecast of ($0.06). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Seaport Res Ptn also issued estimates for Curaleaf's Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.24) EPS.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.09. The firm had revenue of $331.05 million for the quarter, compared to analysts' expectations of $331.87 million. Curaleaf had a negative return on equity of 13.67% and a negative net margin of 14.82%.
Curaleaf Price Performance
Shares of CURLF stock traded down $0.03 during trading on Monday, hitting $0.96. The company had a trading volume of 556,236 shares, compared to its average volume of 744,790. The firm has a market capitalization of $634.20 million, a P/E ratio of -3.31 and a beta of 0.57. Curaleaf has a one year low of $0.88 and a one year high of $6.40. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 1.11. The stock's 50-day moving average price is $1.38 and its 200 day moving average price is $2.10.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
